Tau immunization: a cautionary tale?

[1]  N. Zilka,et al.  First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model , 2014, Alzheimer's Research & Therapy.

[2]  N. Zilka,et al.  Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[3]  F. LaFerla,et al.  p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice , 2014, Neuroscience Letters.

[4]  H. Soares,et al.  Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  Bradley T. Hyman,et al.  The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease , 2014, Neuron.

[6]  S. Hébert,et al.  Specificity of Anti-Tau Antibodies when Analyzing Mice Models of Alzheimer's Disease: Problems and Solutions , 2014, PloS one.

[7]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[8]  T. Golde,et al.  Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease , 2014, The Journal of Neuroscience.

[9]  Zeshan Ahmed,et al.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.

[10]  M. Tolnay,et al.  Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies , 2014, Neuropharmacology.

[11]  J. Winderickx,et al.  Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies , 2014, Acta neuropathologica communications.

[12]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[13]  Robert J. Neely,et al.  Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease , 2013, PloS one.

[14]  D. Karussis,et al.  Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation , 2013, Experimental Neurology.

[15]  F. LaFerla,et al.  Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice , 2013, Journal of neurochemistry.

[16]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[17]  P. Davies,et al.  Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity , 2013, PloS one.

[18]  M. Citron,et al.  Constitutive secretion of tau protein by an unconventional mechanism , 2012, Neurobiology of Disease.

[19]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[20]  M. Pangalos,et al.  Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[21]  Keith A. Vossel,et al.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model , 2012, Proceedings of the National Academy of Sciences.

[22]  L. Buée,et al.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. , 2012, Current Alzheimer research.

[23]  D. Holtzman,et al.  The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain , 2012, Brain Research.

[24]  A. Ittner,et al.  Tau‐targeted treatment strategies in Alzheimer's disease , 2012, British journal of pharmacology.

[25]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[26]  T. Comery,et al.  Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific , 2012, The Journal of Neuroscience.

[27]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[28]  A. Ittner,et al.  Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice , 2011, PloS one.

[29]  D. Holtzman,et al.  Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation , 2011, The Journal of Neuroscience.

[30]  D. Holtzman,et al.  In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice , 2011, The Journal of Neuroscience.

[31]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[32]  E. Sigurdsson,et al.  Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.

[33]  M. Rowan,et al.  Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.

[34]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[35]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[36]  Rudi D'Hooge,et al.  Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.

[37]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[38]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[39]  D. Quartermain,et al.  Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.

[40]  Kai Zhang,et al.  Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport , 2010, Science.

[41]  E. Mandelkow,et al.  Fyn-Tau-Amyloid: A Toxic Triad , 2010, Cell.

[42]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[43]  N. Grigoriadis,et al.  Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice , 2010, Experimental Neurology.

[44]  K. Zahs,et al.  Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.

[45]  J. Dodart,et al.  Isoform‐specific effects of apolipoprotein E on cognitive performance in targeted‐replacement mice overexpressing human APP , 2010, Genes, brain, and behavior.

[46]  J. Trojanowski,et al.  Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.

[47]  D. Selkoe,et al.  Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life , 2009, Neurobiology of Disease.

[48]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[49]  J. Dodart,et al.  Excitotoxic lesions restricted to the dorsal CA1 field of the hippocampus impair spatial memory and extinction learning in C57BL/6 mice , 2008, Neurobiology of Learning and Memory.

[50]  L. Mucke,et al.  Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice , 2008, Neurobiology of Aging.

[51]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[52]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[53]  Ayodeji A. Asuni,et al.  Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.

[54]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[55]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[56]  M. Staufenbiel,et al.  Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage , 2007, Neurobiology of Aging.

[57]  D. Karussis,et al.  Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. , 2006, Archives of neurology.

[58]  C. Lemere,et al.  Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response , 2006, The Journal of Neuroscience.

[59]  J. Trojanowski,et al.  Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice* , 2006, Journal of Biological Chemistry.

[60]  T. Golde,et al.  Anti-Aβ42– and anti-Aβ40–specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model , 2005 .

[61]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[62]  Adriana B Ferreira,et al.  The Generation of a 17 kDa Neurotoxic Fragment: An Alternative Mechanism by which Tau Mediates β-Amyloid-Induced Neurodegeneration , 2005, The Journal of Neuroscience.

[63]  W. H. Jordan,et al.  Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.

[64]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[65]  L. Mucke,et al.  Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation , 2004, Nature Medicine.

[66]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[67]  D. Holtzman,et al.  P4-358 In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and the selective exacerbation of CAA-associated microhemorrhage , 2004, Neurobiology of Aging.

[68]  G. Wenk.  Assessment of Spatial Memory Using the Radial Arm Maze and Morris Water Maze , 2004, Current protocols in neuroscience.

[69]  R. Martins,et al.  Amyloid‐β‐induced toxicity of primary neurons is dependent upon differentiation‐associated increases in tau and cyclin‐dependent kinase 5 expression , 2003, Journal of neurochemistry.

[70]  Charles J. Duffy,et al.  Spatial disorientation in Alzheimer’s disease , 2003, Neurology.

[71]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Staufenbiel,et al.  Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy , 2002, Science.

[73]  D. Schenk.  Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.

[74]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[75]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  K. Ashe.  Learning and memory in transgenic mice modeling Alzheimer's disease. , 2001, Learning & memory.

[77]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[78]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[79]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[80]  Bruce A. Yankner,et al.  Aging renders the brain vulnerable to amyloid β-protein neurotoxicity , 1998, Nature Medicine.

[81]  G. Jicha,et al.  Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.

[82]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[83]  S. Tonegawa,et al.  Hippocampal lesions impair contextual fear conditioning in two strains of mice. , 1996, Behavioral neuroscience.

[84]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[85]  P. Lopresti,et al.  Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[86]  C. Lo,et al.  Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. , 1995, Hybridoma.

[87]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[88]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[89]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[90]  Joseph E LeDoux,et al.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. , 1992, Behavioral neuroscience.

[91]  M. Vandermeeren,et al.  Affinity Purification of Human τ Proteins and the Construction of a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay for Human τ Detection , 1992, Journal of neurochemistry.

[92]  V. Henderson,et al.  Spatial disorientation in Alzheimer's disease. , 1989, Archives of Neurology.

[93]  S. Yen,et al.  Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. , 1988, The Journal of biological chemistry.

[94]  J. Brion,et al.  Both adult and juvenile tau microtubule-associated proteins are axon specific in the developing and adult rat cerebellum , 1988, Neuroscience.

[95]  H. Reiber,et al.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[96]  D. Selkoe,et al.  TAU-SPECIFIC MONOCLONAL AND POLYCLONAL ANTIBODIES SUGGEST THAT TAU IS A MAJOR ANTIGENIC COMPONENT OF ALZHEIMER NEUROFIBRILLARY TANGLES (NFT) , 1986 .

[97]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[98]  D. Olton,et al.  Remembrance of places passed: Spatial memory in rats. , 1976 .

[99]  D. Walsh,et al.  The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. , 2013, Journal of Alzheimer's disease : JAD.

[100]  Robert Lalonde,et al.  Neurologic and motor dysfunctions in APP transgenic mice , 2012, Reviews in the neurosciences.

[101]  D. Quartermain,et al.  Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders. , 2012, Methods in molecular biology.

[102]  M. Ahlijanian,et al.  Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. , 2011, Journal of Alzheimer's disease : JAD.

[103]  Sangmook Lee,et al.  Interneuronal transfer of human tau between Lamprey central neurons in situ. , 2010, Journal of Alzheimer's disease : JAD.

[104]  M. Vandermeeren,et al.  Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes , 2004, Acta Neuropathologica.

[105]  Douglas Wahlsten,et al.  Different data from different labs: lessons from studies of gene-environment interaction. , 2003, Journal of neurobiology.